N. Grunenberg

发表

Diversion of HIV-1 vaccine–induced immunity by gp41-microbiota cross-reactive antibodies

T. Kepler, S. Hammer, H. Liao, 2015, Science.

Antigenic competition in CD4+ T cell responses in a randomized, multicenter, double-blind clinical HIV vaccine trial

J. Kublin, N. Frahm, G. Pantaleo, 2019, Science Translational Medicine.

Oral abstracts of the 21st International AIDS Conference 18–22 July 2016, Durban, South Africa

Michael I. Jordan, Donald A. Jackson, J. G. Ndirangu, 2016, Journal of the International AIDS Society.

A First-in-Human, Randomized, Double-Blind, Placebo-Controlled, Single- and Multiple-Ascending Oral Dose Study To Assess the Safety and Tolerability of LFF571 in Healthy Volunteers

J. Praestgaard, J. Leeds, Jenny C. Yang, 2012, Antimicrobial Agents and Chemotherapy.

A First-inHuman , Randomized , Double-Blind , Placebo-Controlled , Single-and Multiple-Ascending Oral Dose Study To Assess the Safety and Tolerability of LFF 571 in Healthy Volunteers

J. Praestgaard, J. Leeds, Jenny C. Yang, 2012 .

Subtype C ALVAC-HIV and bivalent subtype C gp120/MF59 HIV-1 vaccine in low-risk, HIV-uninfected, South African adults: a phase 1/2 trial

J. Kublin, D. Montefiori, N. Frahm, 2018, The lancet. HIV.

Safety and immunogenicity of a SARS-CoV-2 recombinant protein vaccine with AS03 adjuvant in healthy adults: interim findings from a phase 2, randomised, dose-finding, multi-centre study

N. Michael, R. Canter, N. Rouphael, 2021, medRxiv.

Efficacy of a bivalent (D614 + B.1.351) SARS-CoV-2 Protein Vaccine

Kwaku Poku Asante, S. Gurunathan, N. Michael, 2022, medRxiv.

Rectal and vaginal tissue from intravenous VRC01 recipients show protection against ex vivo HIV-1 challenge.

S. Hammer, M. McElrath, I. Frank, 2021, The Journal of clinical investigation.

Rectal tissue and vaginal tissue from intravenous VRC01 recipients show protection against ex vivo HIV-1 challenge

S. Hammer, M. McElrath, I. Frank, 2021 .

2008 DOSE-RANGING, THREE-DAY MONOTHERAPY STUDY OF THE HCV NS3 PROTEASE INHIBITOR GS-9256

M. Micco, H. Mo, W. Delaney, 2010 .

Antibody and cellular responses to HIV vaccine regimens with DNA plasmid as compared with ALVAC priming: An analysis of two randomized controlled trials

Allan C. deCamp, J. Kublin, D. Montefiori, 2020, PLoS medicine.

Safety, pharmacokinetics, and immunological activities of multiple intravenous or subcutaneous doses of an anti-HIV monoclonal antibody, VRC01, administered to HIV-uninfected adults: Results of a phase 1 randomized trial

J. Mascola, D. Montefiori, R. Bailer, 2017, PLoS medicine.

Analysis of the HVTN 702 Phase 2b-3 HIV-1 vaccine trial in South Africa assessing RV144 antibody and T-cell correlates of HIV-1 acquisition risk.

Lindsay N. Carpp, J. Kublin, M. McElrath, 2022, The Journal of infectious diseases.

Assessment of the Safety and Immunogenicity of 2 Novel Vaccine Platforms for HIV-1 Prevention: A Randomized Trial.

N. Frahm, E. Karita, M. McElrath, 2016, Annals of internal medicine.

Vaccine Efficacy of ALVAC-HIV and Bivalent Subtype C gp120/MF59 in Adults

M. Andrasik, J. Kublin, M. McElrath, 2021, The New England journal of medicine.

Safety and immunogenicity of an AS03-adjuvanted SARS-CoV-2 recombinant protein vaccine (CoV2 preS dTM) in healthy adults: interim findings from a phase 2, randomised, dose-finding, multicentre study

N. Michael, N. Rouphael, C. Diazgranados, 2022, The Lancet Infectious Diseases.

Immune correlates of the Thai RV144 HIV vaccine regimen in South Africa

J. Kublin, D. Montefiori, M. McElrath, 2019, Science Translational Medicine.

Meta-analysis of HIV-1 vaccine elicited mucosal antibodies in humans

G. Pantaleo, M. McElrath, P. Gilbert, 2021, NPJ vaccines.

HIV-1 Vaccine Sequences Impact V1V2 Antibody Responses: A Comparison of Two Poxvirus Prime gp120 Boost Vaccine Regimens

Rachel L. Spreng, P. Gilbert, L. Corey, 2020, Scientific Reports.

Immunogenicity of a novel Clade B HIV-1 vaccine combination: Results of phase 1 randomized placebo controlled trial of an HIV-1 GM-CSF-expressing DNA prime with a modified vaccinia Ankara vaccine boost in healthy HIV-1 uninfected adults

D. Montefiori, S. Buchbinder, N. Frahm, 2017, PloS one.

Uptake of Genital Mucosal Sampling in HVTN 097, a Phase 1b HIV Vaccine Trial in South Africa

G. Gray, G. Churchyard, K. Otwombe, 2014, PloS one.

Single dose pharmacokinetics and absolute bioavailability of mirabegron, a β₃-adrenoceptor agonist for treatment of overactive bladder.

D. Kowalski, Wenhui Zhang, M. van Gelderen, 2012, International journal of clinical pharmacology and therapeutics.

Safety and immune responses after a 12-month booster in healthy HIV-uninfected adults in HVTN 100 in South Africa: A randomized double-blind placebo-controlled trial of ALVAC-HIV (vCP2438) and bivalent subtype C gp120/MF59 vaccines

J. Kublin, D. Montefiori, N. Frahm, 2020, PLoS medicine.

Innate immune signatures to a partially-efficacious HIV vaccine predict correlates of HIV-1 infection risk

Lindsay N. Carpp, J. Kublin, M. McElrath, 2021, PLoS pathogens.

Effects of food intake on the pharmacokinetic properties of mirabegron oral controlled-absorption system: a single-dose, randomized, crossover study in healthy adults.

D. Kowalski, J. Keirns, Wenhui Zhang, 2013, Clinical therapeutics.

Population pharmacokinetics analysis of VRC01, an HIV-1 broadly neutralizing monoclonal antibody, in healthy adults

R. Bailer, P. Gilbert, J. Ledgerwood, 2017, mAbs.

Prediction of Serum HIV-1 Neutralization Titers After Passive Administration of VRC01.

Lindsay N. Carpp, J. Mascola, D. Montefiori, 2019, Journal of Acquired Immune Deficiency Syndromes.

Efficacy of a monovalent (D614) SARS-CoV-2 recombinant protein vaccine with AS03 adjuvant in adults: a phase 3, multi-country study

Kwaku Poku Asante, D. Follmann, M. Robb, 2023, eClinicalMedicine.

Rectal and vaginal tissue from intravenous VRC01 recipients show protection against ex vivo HIV-1 challenge

M. McElrath, A. McDermott, J. Ledgerwood, 2021 .

D. Montefiori, S. Buchbinder, N. Frahm, 2017, PloS one.

Diversion of HIV-1 vaccine–induced immunity by gp41-microbiota cross-reactive antibodies

T. Kepler, S. Hammer, B. Haynes, 2015, Science.

Risk Factors Associated with HIV Acquisition in Males Participating in HIV Vaccine Efficacy Trials in South Africa

M. Andrasik, L. Bekker, Yunda Huang, 2023, AIDS and Behavior.

Polytopic fractional delivery of an HIV vaccine alters cellular responses and results in increased epitope breadth in a phase 1 randomized trial

Allan C. deCamp, N. Frahm, A. Fiore-Gartland, 2024, EBioMedicine.

Safety and immunogenicity after a 30-month boost of a subtype C ALVAC-HIV (vCP2438) vaccine prime plus bivalent subtype C gp120/MF59 vaccine boost (HVTN 100): A phase 1–2 randomized double-blind placebo-controlled trial

C. Diazgranados, Z. Moodie, N. Yates, 2024, PLOS global public health.

Safety and immunogenicity of a subtype C ALVAC-HIV (vCP2438) vaccine prime plus bivalent subtype C gp120 vaccine boost adjuvanted with MF59 or alum in healthy adults without HIV (HVTN 107): A phase 1/2a randomized trial

N. Mgodi, G. Tomaras, C. Diazgranados, 2024, PLoS medicine.